COST MINIMISATION STUDY OF THE BIOLOGICAL TREATMENT OF INFLAMMATORY BOWEL DISEASE: USTEKINUMAB VERSUS VEDOLIZUMAB (submitted in 2019)

COST MINIMISATION STUDY OF THE BIOLOGICAL TREATMENT OF INFLAMMATORY BOWEL DISEASE: USTEKINUMAB VERSUS VEDOLIZUMAB (submitted in 2019)